Company intelligence / Profile preview

BrainsGate

Caesarea, Israel

Ownership: Private
Employees: ~24
Development stage: Other

Overview

BrainsGate’s platform uses a minimally invasive implantable neurostimulator to electrically stimulate the Spheno-Palatine Ganglion (SPG), increasing cerebral blood flow. The company completed early pilot and pivotal trials with promising safety results but did not achieve statistical significance for efficacy in its pivotal trial for acute ischemic stroke. An FDA advisory panel in December 2021 found the device safe but not sufficiently effective to recommend approval at that time. The company continues to explore applications and further studies.

Therapeutic areas: NeurologyCardiovascular
Modalities: DeviceNeurostimulation
Industry: Implantable Medical Devices

Partnerships

Johnson & JohnsonBoston ScientificElron Electronics IndustriesPitango Venture CapitalAlice VenturesAgate Medical InvestmentsInfinity VenturesCipio Partners

Beyond the preview

Go deeper on BrainsGate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrainsGate.

Explore the full profile